About Lanthio Pharma
Lanthio Pharma is a Healthcare company based in Groningen (Netherlands) founded in 2010, and was acquired by MorphoSys in May 2015. Speciality company developing and commercializing therapeutic peptide drugs against difficult to target receptors. Lanthio Pharma has raised $6.27 million across 3 funding rounds from investors including MorphoSys, Rijksdienst voor Ondernemend Nederland and BioGeneration Ventures. Its focus areas include Diversified Pharmaceuticals.
Company details
Lanthio Pharma is committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity. Company is building a growing pipeline of stabilized, receptor specific lanthipeptides with the potential for treatment of fibrosis, heart failure and multiple sclerosis. Pipeline includes LP2 for diabetic nephropathy, lanthi-apelin for heart failure, lanthi-galani for multiple sclerosis and pancyte (indication is confidential). company was acquired by morphosys in 2015
- Headquarters Groningen, Netherlands
- Stage Acquired
- SectorsHealthcare
- Website lanthiopharma.com
- Social LinkedIn
- Acquired by MorphoSys (May 2015)
Funding Insights of Lanthio Pharma
Lanthio Pharma has successfully raised a total of $6.27M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $4.93 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.27M
- Total Rounds 3
- Last Round Debt – Conventional — $4.93M
- Investors Count 4
All 3 funding rounds of Lanthio Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2014 | $4.93M | Debt – Conventional | – | – | |
| Nov 2012 | $6.27M | Series A | – | BioGeneration Ventures, MorphoSys | – |
| Jun 2011 | Seed | – | – |
4 investors in total: 4 institutional.
Investors in Lanthio Pharma
Lanthio Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include MorphoSys, Rijksdienst voor Ondernemend Nederland and BioGeneration Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science focused VC firm investing in startups in Europe | biogenerationventures.com | Naarden, Netherlands | ||
AI, deeptech, and healthcare tech companies are funded by Inkef. | inkef.com | Amsterdam, Netherlands | ||
Provider of subsidies and financial support for businesses | 2014 | rvo.nl | Haag, Germany | |
Therapeutic antibodies for cancer and other diseases are developed. | 1992 | morphosys.com | Planegg, Germany |
Investor details for Lanthio Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Lanthio Pharma
4 dated milestones of Lanthio Pharma across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Lanthio Pharma is founded.
- Funding First funding round.
- Funding Latest funding round, Debt – Conventional, of $4.9M.
- Exit Acquired by MorphoSys.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lanthio Pharma
Complete news archive for Lanthio Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lanthio Pharma
Lanthio Pharma was founded in 2010 and raised its 1st funding round 1 year after it was founded.
Lanthio Pharma is headquartered in Groningen, Netherlands. It is registered at Groningen, Groningen, Netherlands.
Lanthio Pharma is a funded company, having raised a total of $6.27M across 3 funding rounds to date.
Lanthio Pharma is committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary LanthioPep technology, the company is generating peptide drugs that are markedly enhanced for stability and selectivity. Company is building a growing pipeline of stabilized, receptor specific lanthipeptides with the potential for treatment of fibrosis, heart failure and multiple sclerosis. Pipeline includes LP2 for diabetic nephropathy, lanthi-apelin for heart failure, lanthi-galani for multiple sclerosis and pancyte (indication is confidential). company was acquired by morphosys in 2015.
Lanthio Pharma has 4 investors. Key investors include MorphoSys, Rijksdienst voor Ondernemend Nederland, BioGeneration Ventures, and Inkef.
Yes. Lanthio Pharma was acquired by MorphoSys in May 2015.